Completed PHASE2 INTERVENTIONAL 2-arm NCT00955253

Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance (GASNIV)

A Trial of Guanfacine, an Alpha 2 Adrenergic Agonist, for Spatial Neglect and Impaired Vigilance Following Stroke and Focal Brain Damage

Sponsor: Imperial College London

Conditions Hemispatial Neglect Stroke

Interventions Guanfacine Placebo

Updated 10 times since 2017 Last updated: Jan 6, 2020 Started: Apr 30, 2010 Primary completion: Mar 28, 2014 Completion: Mar 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00955253, this PHASE2 trial focuses on Hemispatial Neglect and Stroke and remains completed. Sponsored by Imperial College London, it has been updated 10 times since 2010, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Feb 2020 — Jan 2021 [monthly]

Completed PHASE2
Sep 2019 — Feb 2020 [monthly]

Completed PHASE2
Jun 2018 — Sep 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Imperial College London
Wellcome Trust

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom